<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00411736</url>
  </required_header>
  <id_info>
    <org_study_id>AZI/SCAND/01</org_study_id>
    <nct_id>NCT00411736</nct_id>
  </id_info>
  <brief_title>Scandinavian Cystic Fibrosis Azithromycin Study</brief_title>
  <official_title>Supplementary Oral Azithromycin in Treatment of Intermittent Pseudomonas Aeruginosa Colonization in CF-patients With Inhaled Colistin and Oral Ciprofloxacin; Postponing Next Isolate of Pseudomonas and Prevention of Chronic Infection. A Prospective, Double-blinded, Placebo-controlled Scandinavian Multi-centre Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with Cystic Fibrosis, recurrent airway infection caused by Pseudomonas aeruginosa
      ultimately leads to chronic airway infection. The purpose of this study is to determine
      whether supplementary low-dose azithromycin to standard inhaled colistin and oral
      ciprofloxacin in the treatment of intermittent pseudomonas airway-infection can postpone the
      next episode of intermittent pseudomonas airway-infection and prevent development of chronic
      airway-infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cystic Fibrosis is the most common genetic, inherited, deadly disease in caucasians. The
      disease is characterized by recurrent airway-infections caused by Pseudomonas aeruginosa,
      ultimately leading to chronic airway-infection, which is the main cause of the increased
      morbidity and mortality seen in this disease.

      P. aeruginosa has the ability to change to mucoid phenotype - producing alginate and growing
      in biofilm, which protects the microorganisms from antibiotics and leukocytes. The change in
      phenotype is seen as chronic infection is established and eradication becomes impossible.
      Treatment with long-term, low-dose azithromycin in chronically infected CF-patients can
      improve the clinical condition of the patients. The exact mechanism for this is not known,
      but is possibly a combination of anti-inflammatory effects and the ability of azithromycin to
      inhibit alginate-production. Inhibition of biofilm-formation leaves the bacteria more
      susceptible to the actions of antibiotics and leukocytes.

      Prior to establishment of chronic infection, recurrent, intermittent colonization of the
      airways with non-mucoid P. aeruginosa is seen. Intermittent infections can be treated using a
      combination of antibiotics, thereby postponing the next episode of airway-infection with P.
      aeruginosa.

      The purpose of this study is to clarify wether supplementary azithromycin in the treatment of
      intermittent pseudomonas-infection in CF-patients can lead to further postponement of next
      pseudomonas-colonization and maybe prevent development of chronic infection. This is done in
      a randomised, double-blinded, placebo-controlled multicentre study.

      2 treatments will be compared:

        1. Inhaled colistin and oral ciprofloxacin in combination with oral azithromycin

        2. Inhaled colistin and oral ciprofloxacin in combination with oral placebo.

      The treatment will be given for 3 weeks, and the primary end-point is the time until next
      colonization with P. aeruginosa in the airways of the patients, comparing the 2
      treatment-groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to next airway-colonization (re-colonization) with Pseudomonas aeruginosa</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical condition of the patients (height, weight and lung function)</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriological examination of Pseudomonas aeruginosa (phenotype, resistance)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of Pseudomonas aeruginosa using Pulsed Field Gel Electrophoresis (re-infection caused by identical or new strain)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specific, precipitating pseudomonas-antibodies (establishment of chronic infection)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratification group: Age under 8 years, no CF siblings at home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratification group: Age &gt;/= 8 years, no CF siblings at home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stratification group: Age &gt;/= 8 years, CF siblings at home.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Study medication, azithromycin or placebo</intervention_name>
    <description>Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Projectnumber HSA06-20/1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin or placebo tablets</intervention_name>
    <description>Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <other_name>Project number HSA06-20/1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Cystic Fibrosis based on genotype and/or positive sweat-test

          -  Written informed consent based on written and spoken information

          -  No chronic airway-infections with Gram-negative bacteria

          -  Fertile, sexually active women must use contraception (p-pills, IUD or other methods
             with a similar Pearl-index) when participating in the study

        Exclusion Criteria:

          -  P. aeruginosa in airway secretions obtained less than 3 months prior to inclusion

          -  Chronic infection of the airways caused by Gram-negative bacteria (Burkholderia
             species, Achromobacter xylosoxidans, Pandorea apista or Stenotrophomonas maltophilia)

          -  Chronic infection of the airways caused by P. aeruginosa (chronic infection is defined
             by continuing growth of the microorganism for 6 months and/or an increase in specific,
             precipitating antibodies to a level of at least 2)

          -  Previous infection with a strain of P. aeruginosa resistant to ciprofloxacin or
             colistin

          -  Previous participation in a pseudomonas-vaccination-study

          -  Patients younger than 1 year

          -  Pregnant or lactating women, or sexually active women unwilling to use safe
             contraception (p-pills, IUD or method with similar Pearl-index) when participating in
             the study

          -  Severe insufficiency of the liver or kidneys as judged by the local investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels Hoiby, Prof.M.D.DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Microbiology, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CF-centre Skejby, Skejby Sygehus, Brendstrupgaardsvej 100</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Copenhagen, Rigshospitalet, Blegdamsvej 9</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Bergen, Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Oslo, Ullevaal Universitetssykehus</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Göteborg, Drottning Silvias barn- och ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Lund, Universitetssjukhuset i Lund</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Stockholm, Karolinska Universitetssjukhuset, Huddinge</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CF-centre Uppsala, Akademiska Barnsjukhuset</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000 Oct;16(4):749-67. Review.</citation>
    <PMID>11106223</PMID>
  </reference>
  <reference>
    <citation>Høiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005 Aug;4 Suppl 2:49-54. Review.</citation>
    <PMID>16023416</PMID>
  </reference>
  <reference>
    <citation>Valerius NH, Koch C, Høiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet. 1991 Sep 21;338(8769):725-6.</citation>
    <PMID>1679870</PMID>
  </reference>
  <reference>
    <citation>Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002 Sep 28;360(9338):978-84.</citation>
    <PMID>12383667</PMID>
  </reference>
  <reference>
    <citation>Gillis RJ, White KG, Choi KH, Wagner VE, Schweizer HP, Iglewski BH. Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2005 Sep;49(9):3858-67.</citation>
    <PMID>16127063</PMID>
  </reference>
  <reference>
    <citation>Hansen CR, Pressler T, Koch C, Høiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros. 2005 Mar;4(1):35-40.</citation>
    <PMID>15752679</PMID>
  </reference>
  <reference>
    <citation>Jaffé A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet. 1998 Feb 7;351(9100):420.</citation>
    <PMID>9482305</PMID>
  </reference>
  <reference>
    <citation>Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003 Oct 1;290(13):1749-56.</citation>
    <PMID>14519709</PMID>
  </reference>
  <reference>
    <citation>Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax. 2002 Mar;57(3):212-6.</citation>
    <PMID>11867823</PMID>
  </reference>
  <reference>
    <citation>Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med. 1995 Dec 29;99(6A):26S-30S.</citation>
    <PMID>8585531</PMID>
  </reference>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <last_update_submitted>March 13, 2014</last_update_submitted>
  <last_update_submitted_qc>March 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Christine Hansen</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Intermittent pulmonary infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

